These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12082199)

  • 41. Alveolar hemorrhage: an underdiagnosed complication of treatment with glycoprotein IIb/IIIa inhibitors.
    Iskandar SB; Kasasbeh ES; Mechleb BK; Garcia I; Jackson A; Fahrig S; Albalbissi K; Henry PD
    J Interv Cardiol; 2006 Aug; 19(4):356-63. PubMed ID: 16881986
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors.
    Blankenship JC
    Am Heart J; 1999 Oct; 138(4 Pt 2):287-96. PubMed ID: 10502234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
    Glaser R; Glick HA; Herrmann HC; Kimmel SE
    J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment.
    Vahdat B; Canavy I; Fourcade L; Garcia E; Quilici J; Bonnet JL; Bory M
    Catheter Cardiovasc Interv; 2000 Feb; 49(2):177-80. PubMed ID: 10642768
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy.
    Reddy MS; Carmody TJ; Kereiakes DJ
    Catheter Cardiovasc Interv; 2001 Apr; 52(4):486-8. PubMed ID: 11285605
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An audit of the use and complications of glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention against national UK standards.
    Sheikh A; Baig K
    Cardiovasc Revasc Med; 2006; 7(4):237-9. PubMed ID: 17174871
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute profound thrombocytopenia without bleeding complications after abciximab administration.
    Elmi F; Oza R; Mascarenhas DA
    J Invasive Cardiol; 1999 May; 11(5):313-5. PubMed ID: 10745539
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinical safety using the thrombocyte aggregation inhibitor c7E3 in interventional cardiology in 520 patients].
    Machnig T; Zahn R; Rustige J; Gödicke J; Marsalek P; Gulba D
    Z Kardiol; 1997 Dec; 86(12):975-81. PubMed ID: 9499495
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PCI with and without abciximab after upstream eptifibatide use: outcomes in high-risk patients.
    Applegate RJ; Grabarczyk MA; Sane DC; Sacrinty MT; Goodin JE; Statonk GS; Baki TT; Gandhi SK; Kutcher MA; Little WC
    J Invasive Cardiol; 2006 Dec; 18(12):604-13. PubMed ID: 17197712
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty.
    Ellis SG; Tcheng JE; Navetta FI; Muller DW; Weisman HF; Smith C; Anderson KM; Califf RM; Topol EJ
    Coron Artery Dis; 1993 Feb; 4(2):167-75. PubMed ID: 8269208
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Pharmacodynamics, safety, and clinical effects of a novel glycoprotein IIb/IIIa antagonist framon during high risk coronary angioplasty].
    Mazurov AV; Pevzner DV; Semenov AV; Antonova OA; Dudnik OA; Khaspekova SG; Vlasik TN; Samko AN; Staroverov II; Ruda MIa
    Kardiologiia; 2002; 42(6):8-17. PubMed ID: 12494124
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Emergent operation for percutaneous coronary rupture after abciximab administration.
    Roberts CS; Bocanegra NR
    Ann Thorac Surg; 2001 Jun; 71(6):2024-6. PubMed ID: 11426792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Abciximab-induced delayed profound thrombocytopaenia.
    Jbara M; Bhogal S; Bajaj K; Chhabra L
    BMJ Case Rep; 2017 Jun; 2017():. PubMed ID: 28576909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute profound thrombocytopenia after abciximab therapy during coronary angioplasty.
    Joseph T; Marco J; Gregorini L
    Clin Cardiol; 1998 Nov; 21(11):851-2. PubMed ID: 9825202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors.
    Kleiman NS
    Am Heart J; 1999 Oct; 138(4 Pt 2):263-75. PubMed ID: 10502232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab.
    Moon SJ; Yoon HJ; Her SH; Lee JM; An HJ; Lee YJ; Jin SW
    Korean J Intern Med; 2008 Sep; 23(3):156-60. PubMed ID: 18787370
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glycoprotein Wars and PIECE activists.
    Goldberg S
    J Invasive Cardiol; 2003 Jun; 15(6):324-5. PubMed ID: 12777671
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.